Cannabidiol is indicated for use as adjunctive therapy of seizures associated with tuberous sclerosis complex (TSC) for patients 2 years of age and older.
|NCPE Assessment Process||Complete|
|Rapid review commissioned||09/06/2021|
|Rapid review completed||08/07/2021|
|Rapid Review outcome||A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of cannabidiol (Epidyolex®) compared with the current standard of care, on the basis of the proposed price relative to currently available therapies.|